Kiora grants 55,000 stock options to EVP Lane

EVP Clinical and Regulatory at Kiora Pharmaceuticals received a 55,000-share stock option grant at a $2.67 exercise price with three-year vesting.

Rhea-AI Filing Summary

Kiora Pharmaceuticals Inc. (KPRX) reported that executive Keith J. Lane, EVP, Clinical and Regulatory, received a grant of stock options for 55,000 shares of Common Stock on September 17, 2026. The options have an exercise price of $2.67 per share and expire on September 17, 2036.

According to the award terms, the option becomes exercisable as to one-third of the shares on September 17, 2027, with the remaining balance vesting monthly on the last day of each month over the following two years, subject to Mr. Lane’s continuous service. No Rule 10b5-1 trading plan is reported for this grant.

Insider Trade Summary

Grant/Award: 55,000 shares

Grant/Award 1 txn

Insider Lane Keith J.

Role Insider

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	55,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 55,000 contracts (Direct)

Footnotes (1)

1. F1. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on September 17, 2027, and the remaining balance vests monthly on the last day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

Key Figures

Stock options granted: 55,000 options Exercise price: $2.67 per share Expiration date: September 17, 2036 +2 more

5 metrics

Stock options granted 55,000 options Grant to EVP, Clinical and Regulatory, on September 17, 2026

Exercise price $2.67 per share Exercise price of the 55,000 stock options granted

Expiration date September 17, 2036 Expiration of stock option grant to Keith J. Lane

Initial vesting date September 17, 2027 One-third of the option shares become exercisable on this date

Underlying shares per option grant 55,000 shares of Common Stock Each option relates to one share of Kiora Pharmaceuticals Common Stock

Key Terms

Stock Option, Common Stock, vesting, continuous service

4 terms

Stock Option financial

"The reporting person received an option to purchase Common Stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Common Stock financial

"option to purchase Common Stock from the Issuer pursuant to the Plan"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"remaining balance vests monthly on the last day of each calendar month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the reporting person's continuous service through each such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KPRX report for Keith J. Lane?

Kiora Pharmaceuticals reported that EVP, Clinical and Regulatory, Keith J. Lane received a grant of stock options for 55,000 shares of Common Stock on September 17, 2026, at an exercise price of $2.67 per share, expiring on September 17, 2036.

What is the vesting schedule for the 55,000 KPRX stock options granted to Keith J. Lane?

The option for 55,000 shares vests as follows: one-third of the shares on September 17, 2027, and the remaining shares vest monthly on the last day of each calendar month for two years thereafter, subject to Mr. Lane’s continuous service.

What is the exercise price and expiration date of the KPRX options granted to Keith J. Lane?

The options granted to Keith J. Lane have an exercise price of $2.67 per share and an expiration date of September 17, 2036, giving him the right to purchase Kiora Pharmaceuticals Common Stock at that price until expiration, once vested.

How many KPRX derivative securities does Keith J. Lane hold after this Form 4 transaction?

After the reported transaction, Keith J. Lane holds 55,000 stock options directly. These options each relate to one share of Kiora Pharmaceuticals Common Stock and reflect his position following the grant reported on September 17, 2026.

Was the KPRX stock option grant to Keith J. Lane made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox as not checked, and the footnotes do not state that the grant was made pursuant to a Rule 10b5-1 trading plan.

Is Keith J. Lane a director or ten percent owner of KPRX according to this Form 4?

According to the Form 4, Keith J. Lane is reported as EVP, Clinical and Regulatory and is not listed as a director or ten percent owner of Kiora Pharmaceuticals Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 09:36 PM Accepted by SEC EDGAR 09/17/2026 - 09:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lane Keith J.

(Last) (First) (Middle)

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CALIFORNIA 92024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			EVP, Clinical and Regulatory

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.67	09/17/2026		A		55,000		(1)	09/17/2036	Common Stock	55,000	$0	55,000	D

Explanation of Responses:

1. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on September 17, 2027, and the remaining balance vests monthly on the last day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)